RxDoctor Payments Data

Matthew Citron, DO

Ophthalmology · Southfield, MINPI 1942258306

Payments from drug & device makers

$2,450in general payments, 2019–2025

Across 65 payments — averaging $37.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$968
  • Alcon$464
  • AbbVie$434
  • NEW World Medical,inc.$321
  • Thea Pharma Inc.$118
  • Aerie Pharmaceuticals, Inc.$52
  • plus $93 from 5 others

What the payments were for

  • Food & beverage$2,450100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,450 in reported general payments places this provider in the 65th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$482,133
Medicare patients
872
Services billed
6,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost161$78,712
Latanoprost3,749$70,408
RhopressaNetarsudil Mesylate149$60,726
LumiganBimatoprost130$46,016
Prednisolone Acetate849$43,019
CombiganBrimonidine Tartrate/Timolol103$41,867
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,645$40,652
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol203$39,381
RestasisCyclosporine22$31,578
Brimonidine Tartrate1,345$26,474
Timolol Maleate1,093$24,011
Brinzolamide105$20,289
SimbrinzaBrinzolamide/Brimonidine Tart46$14,464
Alphagan PBrimonidine Tartrate22$12,300
Loteprednol Etabonate61$12,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$52$139,438310 claims
AbbVieLumigan, Combigan, Restasis, Alphagan P$434$131,761277 claims
AlconSimbrinza, Azopt$464$19,77157 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$16$12,27561 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →